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Effects of the selective GSK3B inhibitor, tideglusib, on ethanol consumption,
anxiety-like behavior, taste preference, and downstream proteins
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Department of Pharmacology and Toxicology, Program in Neuroscience and VCU Alcohol Research Center, Virginia Commonwealth University, Richmond VA 23298-USA.
*corresponding author. Email: gottliebs2@vcu.edu

INTRODUCTION

METHODS

ANXIETY-LIKE BEHAVIOR

CONCLUSION

Glycogen synthase kinase 3 beta (Gsk3b) has previously been
identified as a central member of a gene network highly regulated
by acute ethanol in the mouse medial prefrontal cortex (mPFC). We
have demonstrated modulations in GSK3B abundance influence
ethanol consumption in rodent models, showing overexpression
increased ethanol consumption (fig. 1) while knock-out produced a
decrease (fig. 2).

• C57BL/6J males and females received i.g. 200mg/kg
tideglusib, except drinking-in-the-dark (males;100mg/kg
i.p.)

Tideglusib has no effect on anxiety-like behavior in
light-dark box; locomotion transiently increases

These data support use of tideglusib as a therapeutic in
treatment of AUD.

Furthermore, we have shown pharmacological inhibition with the
selective GSK3B inhibitor, tideglusib significantly decreased binge
ethanol consumption and preference in a two-bottle choice,
intermittent ethanol access (IEA) paradigm when administered prior
to ethanol access (fig. 3).

GSK3B could be a target for treatment of alcohol use disorder (AUD),
with tideglusib serving as a novel therapeutic. Here we report
tideglusib’s actions on ethanol consumption in a drinking in the
dark (DID) model and investigate tideglusib-induced responses in
other behaviors to further assess its potential as a therapeutic
agent for AUD. We additionally investigate tideglusib modulation
of phosphorylation of downstream GSK3B targets involved in
synaptic plasticity and neurotransmission.
GSK3B Overexpression
Males

Females

GSK3B Deletion

Fig 1. Viral-mediated overexpression of
GSK3B in mPFC (A) increases EtOH
consumption (g/kg) at higher EtOH
concentrations, and (B) increases EtOH
preference at medium concentrations in
male mice (van der Vaart et al, 2018).

• Drinking-in-the-dark (DID): Mice given 20% ethanol 4-hours,
4-days/week x 3 weeks and then i.p. tideglusib or vehicle x 4
days in a Latin Square design with ethanol consumption
measured daily

• Western Blots: Mice received tideglusib or vehicle i.g.
3x/week for 2-weeks and mPFC assayed for phosphorylated
and total GSK3B, Dynamin1, and PSD-95.
*

*

Tideglusib has no effect on percent time spent in the light nor
percent distance traveled in the light. However, tideglusib does
produce a transient increase in total locomotion (*p<0.05) within
the first 5-minutes of testing. This effect dissipates during the last 5minutes of testing and is non-significant when the 5-minute bins are
collapsed

Total Dynamin1 levels are elevated with tideglusib treatment.
Dynamin1 is central to the activity-dependent bulk endocytosis
(ADBE) pathway, which recycles presynaptic vesicles following
neurotransmitter release. ADBE relies on rephosphorylation of
Dynamin1 by GSK3β to prepare it for the next round of ADBE. Our
observation of increased total not phospho- Dynamin1 likely
represents a compensatory response in Dynamin1 to account for
loss of GSK3B activity and may provide insight to the mechanism
through which tideglusib is carrying out its actions on ethanol
behaviors.

DOWNSTREAM PROTEINS
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Tideglusib decreases ethanol consumption during
drinking-in-the-dark

Tideglusib decreases ethanol consumption compared to control
injected mice. Effects are quick to washout, with consumption
returning to baseline within one week of no drug treatment

*

Tideglusib has no effect on taste preference for
either quinine or saccharin

HYPOTHESIS
Tideglusib will decrease ethanol consumption while leaving other
behaviors unaffected, suggesting utility as a therapeutic in
treatment of AUD. Western blotting will reveal differential
regulation of proteins downstream of GSK3B, providing evidence
for a potential mechanism for tideglusib’s effects.

GSK3B is ubiquitously expressed throughout the brain, making it
vital to assess effects of global inhibition on behaviors outside of
ethanol-consumption as well. There were no actions of tideglusib
on anxiety-like phenotypes. However, tideglusib transiently
increased overall locomotion in mice, likely through actions
within the basal ganglia.

ETHANOL CONSUMPTION

TASTE PREFERENCE
Fig 3. Pharmacological inhibition of GSK3B with tideglusib (200mg/kg) via oral gavage
(i.g) decreases binge (2hr) ethanol consumption in (A) male (p<0.0001) and (B) female
(p<0.01) mice

Tideglusib had no influence on taste preference for either
adulterant. The perceived taste of ethanol is an important
determinant of consumption, yet we show tideglusib is likely not
reducing alcohol consumption by altering taste in the mouse.

• Taste Preference: Mice received tideglusib x 6 days and then
tested daily for saccharin or quinine taste preference.

Fig 2. Viral-mediated deletion of GSK3B in
mPFC (A) decreases EtOH consumption
(g/kg) and (B) preference at high EtOH
concentrations (van der Vaart, 2018).

B

Here we show tideglusib significantly decreases ethanol
consumption in the DID model of binge drinking. Tideglusib is
fast acting to decrease consumption, even in mice habituated to
ethanol drinking, suggesting utility in lowering ethanol
consumption prior to onset of a relapse event.

• Light/Dark Box: Mice gavaged with tideglusib or vehicle and
i.p. injected with 1.8g/kg ethanol or saline then tested for
10-min.

GSK3B Inhibition with tideglusib
A

Tideglusib is clinically available and is in phase II clinical trials for
Alzheimer’s disease, supranuclear palsy, and other neurological
disorders.

*
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